Characteristics of the 72 patients with severe chronic ITP before romiplostim administration
| Characteristic . | Value . |
|---|---|
| Male, n (%) | 28 (39) |
| Median age, y (range) | 63 (20-91) |
| Baseline platelet count, × 109/L, median (range) | 11 (1-60) |
| ITP duration before romiplostim, y, median (range) | 6 (0.1-49) |
| Previous therapies | |
| Median, n (range) | 5 (2-12) |
| Prednisone, n (%) | 72 (100) |
| IVIg, n (%) | 70 (97) |
| Rituximab, n (%) | 65 (90) |
| Splenectomy, n (%) | 39 (54) |
| Azathioprine, n (%) | 21 (29) |
| Intravenous cyclophosphamide pulse(s) | 13 (18) |
| Patients with concomitant therapies at baseline, n (%) | 49 (68) |
| Prednisone | 29 (40) |
| IVIg | 29 (40) |
| Immunosuppressants | 8 (11) |
| Characteristic . | Value . |
|---|---|
| Male, n (%) | 28 (39) |
| Median age, y (range) | 63 (20-91) |
| Baseline platelet count, × 109/L, median (range) | 11 (1-60) |
| ITP duration before romiplostim, y, median (range) | 6 (0.1-49) |
| Previous therapies | |
| Median, n (range) | 5 (2-12) |
| Prednisone, n (%) | 72 (100) |
| IVIg, n (%) | 70 (97) |
| Rituximab, n (%) | 65 (90) |
| Splenectomy, n (%) | 39 (54) |
| Azathioprine, n (%) | 21 (29) |
| Intravenous cyclophosphamide pulse(s) | 13 (18) |
| Patients with concomitant therapies at baseline, n (%) | 49 (68) |
| Prednisone | 29 (40) |
| IVIg | 29 (40) |
| Immunosuppressants | 8 (11) |